134-46-3
Chemical Structure
FdUMP triethylammonium
Synonym(s): 2’-Deoxy-5-Fluorouridine 5’-phosphate triethylammonium
- CAS No.: 134-46-3
- Formula:C21H42FN4O8P
- Molecular Weight:528.55
IUPAC Name: triethylamine hemi(((2R,3S,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3-hydroxytetrahydrofuran-2-yl)methyl phosphate)
InChIKey: GMLOOKPICKIMMC-OJSHLMAWSA-N
SMILES: O[C@H]1C[C@H](N(C(N2)=O)C=C(F)C2=O)O[C@@H]1COP(O)(O)=O.CCN(CC)CC.CCN(CC)CC
Biological Activity: FdUMP triethylammonium (2'-Deoxy-5-Fluorouridine 5'-phosphate triethylammonium) is the active metabolite nucleotide of 5-Fluorouracil (HY-90006), with an IC50 of 1.13 μM against human Thymidylate Synthase. FdUMP triethylammonium covalently inhibits the catalytic cycle of thymidylate synthase, blocking dTMP production, which in turn leads to inhibition of DNA synthesis. FdUMP triethylammonium can serve as a core active component of nanoformulations for cancer-related research, such as colorectal cancer, esophageal cancer, and hepatocellular carcinoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FdUMP triethylammonium | 99.90% | FdUMP triethylammonium (2'-Deoxy-5-Fluorouridine 5'-phosphate triethylammonium) is the active metabolite nucleotide of 5-Fluorouracil (HY-90006), with an IC50 of 1.13 μM against human Thymidylate Synthase. FdUMP triethylammonium covalently inhibits the catalytic cycle of thymidylate synthase, blocking dTMP production, which in turn leads to inhibition of DNA synthesis. FdUMP triethylammonium can serve as a core active component of nanoformulations for cancer-related research, such as colorectal cancer, esophageal cancer, and hepatocellular carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dasari M, et al. Discovery of 5'-Substituted 5-Fluoro-2'-deoxyuridine Monophosphate Analogs: A Novel Class of Thymidylate Synthase Inhibitors. ACS pharmacology & translational science. 2023 May 12;6(5):702-709.
- [2]. Guo J, et al. Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Molecular cancer. 2021 Jan 06;20(1):10.
- [3]. Cao W, et al. Lipid Nanoparticular Codelivery System for Enhanced Antitumor Effects by Ferroptosis-Apoptosis Synergistic with Programmed Cell Death-Ligand 1 Downregulation. ACS nano. 2024 Jul 02;18(26):17267-17281.
